NEONATAL OUTCOME IN WOMEN TREATED FOR THE ANTIPHOSPHOLIPID SYNDROME DURING PREGNANCY

The aim of this study was to determine the neonatal outcome in women w ith well-characterized antiphospholipid syndrome treated during pregna ncy with low-dose aspirin. We compared 38 babies born after 36 pregnan cies of 33 women diagnosed as having antiphospholipid syndrome with a group of 38 control infants matched for the same gestational age at bi rth. In all 76 newborns we studied the maternal events associated with the antiphospholipid syndrome, mothers' treatment and neonatal data. All mothers with antiphospholipid syndrome were treated with low-dense aspirin. Prednisone was only prescribed due to maternal complications and heparin in a case of thrombosis. No significant relation was foun d between maternal treatment and neonatal complications. The prematuri ty rate in these newborns was high 14% and the neonatal mortality (5.8 %) was only associated with extreme prematurity (p < 0.001). In our po pulation the overall rate of neonatal complications was higher than in the general population, but when compared with a similar group of new borns no significant differences were found. Our results suggest that primary antiphospholipid syndrome appears to be improved by low-dose a spirin treatment, with a high rate of neonatal survival (95%). Except for prematurity and its potential associated complications, fetal and neonatal outcome is very favourable and no significant relation betwee n maternal treatment and neonatal pathology has been detected.